ABBV - Company ID 0001551152
The table below shows AbbVie Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Revenue | $17.40B | $16.99B | $15.00B | $16.62B | $15.78B | $15.42B |
| Cost of revenue | $4.29B | $4.29B | $4.22B | - | $5.30B | $4.35B |
| Gross profit | - | - | - | $12.07B | - | - |
| R&D | - | - | - | - | - | - |
AbbVie Inc. reported annual revenue of $61.16B for fiscal year 2025. That is up 8.6% from $56.33B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $25.64B (FY 2016) to $61.16B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $4.09B |
| $3.63B |
| $3.58B |
| - |
| $3.57B |
| $3.25B |
| Operating income | $6.27B | $6.43B | $3.99B | - | $1.90B | $4.89B |
| Income tax | $609.00M | $662.00M | $342.00M | - | $526.00M | $613.00M |
| Net income | $4.22B | $3.61B | $695.00M | $1.82B | $186.00M | $938.00M |
| EPS (diluted) | $2.37 | $2.03 | $0.39 | $1.02 | $0.10 | $0.52 |